Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational services; and biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. Further, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Revenue projections:

Revenue projections for LAURUSLABS
Revenue projections for LAURUSLABS

Investors may react cautiously to news that LAURUSLABS's revenues are forecasted to be lower than last year's. Such declines are likely to have a negative effect on the company's bottom line, which can lead to concerns about profitability and hinder investor confidence in the company's future performance.

Financial Ratios:

currentRatio 0.000000
forwardPE 60.460945
debtToEquity 67.300000
earningsGrowth 2.977000
revenueGrowth 0.184000
grossMargins 0.521240
operatingMargins 0.126540
trailingEps 3.710000
forwardEps 23.370000

Laurus Labs Limited's forward PE being elevated could limit price appreciation and heighten the risk of a correction. Investors need to carefully assess this parameter in combination with other fundamentals to determine whether the stock is overvalued.
With earnings and revenue growth in positive territory, LAURUSLABS is projected to expand its business. This strong financial performance suggests the company will continue to grow, as increased profitability and sales drive future success.
Laurus Labs Limited's forward EPS exceeding its trailing EPS means the company is expected to be more profitable this year than last. This suggests an upward trend in earnings, with forecasts indicating that Laurus Labs Limited's financial performance will improve in the current financial year.

Price projections:

Price projections for LAURUSLABS
Price projections for LAURUSLABS

LAURUSLABS's price projections have been revised upward over time, suggesting that analysts are becoming more confident in the company's future. This trend points to increased optimism about LAURUSLABS's ability to grow.

Recommendation changes over time:

Recommendations trend for LAURUSLABS
Recommendations trend for LAURUSLABS


Analysts have recently developed a sell bias for LAURUSLABS, suggesting caution when making investment decisions. Investors are advised to rely on a broad range of market indicators rather than solely on this bias to ensure a more comprehensive understanding of the stock's potential before taking action.